Burning Rock Biotech (NASDAQ:BNR – Get Free Report) and Altimmune (NASDAQ:ALT – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.
Valuation & Earnings
This table compares Burning Rock Biotech and Altimmune”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Burning Rock Biotech | $514.43 million | 0.27 | -$7.92 million | ($0.87) | -15.25 |
| Altimmune | $26,000.00 | 9,916.55 | -$88.09 million | ($0.72) | -1.84 |
Profitability
This table compares Burning Rock Biotech and Altimmune’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Burning Rock Biotech | -13.60% | -12.98% | -8.59% |
| Altimmune | N/A | -29.26% | -25.48% |
Institutional & Insider Ownership
30.0% of Burning Rock Biotech shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 30.3% of Burning Rock Biotech shares are held by company insiders. Comparatively, 1.6% of Altimmune shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent recommendations for Burning Rock Biotech and Altimmune, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Burning Rock Biotech | 1 | 0 | 0 | 0 | 1.00 |
| Altimmune | 1 | 1 | 8 | 0 | 2.70 |
Altimmune has a consensus price target of $14.33, suggesting a potential upside of 981.76%. Given Altimmune’s stronger consensus rating and higher probable upside, analysts clearly believe Altimmune is more favorable than Burning Rock Biotech.
Volatility and Risk
Burning Rock Biotech has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.16, meaning that its share price is 84% less volatile than the S&P 500.
Summary
Altimmune beats Burning Rock Biotech on 8 of the 14 factors compared between the two stocks.
About Burning Rock Biotech
Burning Rock Biotech is a precision oncology company that develops and provides next-generation sequencing tests for cancer. Its testing uses tissue and blood samples to help inform treatment decisions, monitor disease and support cancer research. The company also provides research and clinical-trial services to pharmaceutical companies, including support for the development of cancer therapies and diagnostic tests. Burning Rock is headquartered in Guangzhou, China, and its business primarily serves the Chinese healthcare and life sciences markets.
About Altimmune
Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune’s work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine.
Receive News & Ratings for Burning Rock Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Burning Rock Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
